Publication | Open Access
CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells.
1.1K
Citations
41
References
1996
Year
Lymphocyte DevelopmentImmune RegulationImmunologyPathologyCd4 T Cell ResponsesInnate ImmunityImmune SystemImmune DysregulationInflammationDendritic Cell MaturationMature Dendritic CellsImmunological MemoryAutoimmune DiseaseGranulocyteAutoimmunityT Cell ImmunityCell BiologyDendritic CellsImmune Cell DevelopmentCd14+ Blood MonocytesImmunomodulationDendritic Cell BiologyCellular Immune ResponseMedicine
Dendritic cells are potent antigen‑presenting cells that initiate primary immune responses, yet the intermediate stages of their development remain unknown. The study aimed to identify culture conditions that generate large numbers of dendritic cells from purified monocytes to facilitate their characterization in autoimmune disease, graft rejection, and HIV. CD14+ monocytes cultured with GM‑CSF, IL‑4, and TNF‑α for 7 days differentiated into CD1a+ CD83+ mature dendritic cells that displayed typical phenotypic and morphologic features and were the most potent stimulators in allogeneic mixed leukocyte reactions.
Dendritic cells are potent antigen-presenting cells that initiate primary immune responses. Although dendritic cells derive from bone marrow stem cells, the intermediate stages in their development remain unknown. In this study, plastic-adherent blood monocytes (CD14+, CD1a-) cultured for 7 days with granulocyte-monocyte colony-stimulating factor, interleukin 4, and tumor necrosis factor alpha were shown to differentiate into CD1a+ CD83+ dendritic cells. These cells displayed all phenotypic and morphologic characteristics of mature dendritic cells and were the most potent stimulatory cells in allogeneic mixed leukocyte reactions. The identification of specific culture conditions that generate large numbers of dendritic cells from purified monocytes uncovers an important step in dendritic cell maturation that will allow the further characterization of their role in autoimmune diseases, graft rejection, and human immunodeficiency virus infection.
| Year | Citations | |
|---|---|---|
Page 1
Page 1